A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity

Experimental Biology and Medicine

Volumn 236, Issue 12, 2011, Pages 1468-1476

  Zhao, Wentao ^a,b   Du, Fen ^a,c   Zhang, Michelle ^a   Sun, Shengfang ^d   Yu, Hong ^c   Fan, Daping ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b TIANJIN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Apolipoprotein E; Atherosclerosis; Cholesterol efflux; HDL; Inflammation; Macrophage

Indexed keywords

1,2 DIMYRISTOYL(D54) SN GLYCERO 3 PHOSPHOCHOLINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; CHITIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE; PHOSPHORYLCHOLINE; SEPHAROSE; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL CELL; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; CELL VACUOLE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NONHUMAN; PH MEASUREMENT; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; STRUCTURE ANALYSIS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BINDING SITES; CELL LINE; ESCHERICHIA COLI; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MICE; MICE, INBRED C57BL; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 82755179955     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2011.011169     Document Type: Article

References (35)

1. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370-8
2. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:712-9
3. Takahashi Y, Smith JD. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc Natl Acad Sci USA 1999;96:11358-63
4. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005;15:158-61
5. Mendez AJ. The promise of apolipoprotein A-I mimetics. Curr Opin Endocrinol Diabetes Obes 2010;17:171-6
6. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat Rev Cardiol 2009;6:455-63
7. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 1994;91:9607-11
8. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999;100:1816-22
9. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003;108:661-3
10. Nicholls SJ, Uno K, Kataoka Y, Nissen SE. ETC-216 for coronary artery disease. Expert Opin Biol Ther 2011;11:387-94
11. Kaul S, Rukshin V, Santos R, Azarbal B, Bisgaier CL, Johansson J, Tsang VT, Chyu KY, Cercek B, Mirocha J, Shah PK. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003;107:2551-4
12. Smith JD. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs 2010;11:989-96
13. Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994;45:249-302
14. Plump AS, Smith JD, Hayek T, Aalto-Setaletal K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343-53
15. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-71
16. Shimano H, Yamada N, Katsuki M, Shimada M, Gotoda T, Harada K, Murase T, Fukazawa C, Takaku F, Yazaki Y. Overexpression of apolipoprotein E in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia. Proc Natl Acad Sci USA 1992;89:1750-4
17. Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999;10:207-17
18. Hui DY. Apolipoprotein E-induced cell signaling in the vessel wall. Rev Endocr Metab Disord 2004;5:335-41
19. Saito H, Dhanasekaran P, Baldwin F, Weisgraber KH, Lund-Katz S, Phillips MC. Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles. J Biol Chem 2001;276:40949-54
20. Lu B, Morrow JA, Weisgraber KH. Conformational reorganization of the four-helix bundle of human apolipoprotein E in binding to phospholipid. J Biol Chem 2000;275:20775-81
21. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991;252:1817-22
22. Hasty AH, Linton MF, Swift LL, Fazio S. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J Lipid Res 1999;40:1529-38
23. Nikoulin IR, Curtiss LK. An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J Clin Invest 1998;101:223-34
24. Datta G, Chaddha M, Garber DW, Chung BH, Tytler EM, Dashti N, Bradley WA, Gianturco SH, Anantharamaiah GM. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000;39:213-20
25. Vedhachalam C, Narayanaswami V, Neto N, Forte TM, Phillips MC, Lund-Katz S, Bielicki JK. The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry 2007;46:2583-93
26. Gupta H, White CR, Handattu S, Garber DW, Datta G, Chaddha M, Dai L, Gianturco SH, Bradley WA, Anantharamaiah GM. Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation 2005;111:3112-8
27. Singh K, Chaturvedi R, Asim M, Barry DP, Lewis ND, Vitek MP, Wilson KT. The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappaB activation. J Biol Chem 2008;283:16752-61
28. Li FQ, Sempowski GD, McKenna SE, Laskowitz DT, Colton CA, Vitek MP. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J Pharmacol Exp Ther 2006;318:956-65
29. Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 2010;51:1496-503
30. Garber DW, Handattu S, Aslan I, Datta G, Chaddha M, Anantharamaiah GM. Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 2003;168:229-37
31. Datta G, White CR, Dashti N, Chaddha M, Palgunachari MN, Gupta H, Handattu SP, Garber DW, Anantharamaiah GM. Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Atherosclerosis 2010;208:134-41
32. Fan D, Li Q, Korando L, Jerome WG, Wang J. A monomeric human apolipoprotein E carboxyl-terminal domain. Biochemistry 2004;43:5055-64
33. Hoover DM, Lubkowski J. DNA Works: an automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res 2002;30:e43
34. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010;30:1430-8
35. Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J Am Coll Cardiol 2008;51:1104-9